NVAX Q3 2018 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-7.4% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$42M-541.7% margin

Net Income

-$45M-576.2% margin

EPS (Diluted)

$-2.33

QoQ Revenue Growth

-28.2%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$250M

Total Liabilities

$377M

Stockholders' Equity

-$127M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$8M	-7.4%
Gross Profit	$8M	$8M	-7.4%
Operating Income	-$42M	-$42M	-0.7%
Net Income	-$45M	-$45M	+0.1%